# Comparison between internal and external validation of in vivo 31P MRS quantification

J. Dudley<sup>1</sup>, W-J. Chu<sup>2,3</sup>, X. Wang<sup>1</sup>, M. M. Norris<sup>1</sup>, and J-H. Lee<sup>1,3</sup>

<sup>1</sup>Biomedical Engineering, University of Cincinnati, Cincinnati, OH, United States, <sup>2</sup>Psychiatry, University of Cincinnati, Cincinnati, OH, United States, <sup>3</sup>Center for Imaging Research, University of Cincinnati, Cincinnati, OH, United States

#### **Introduction**:

Quantification of MRS signals is possible with an internal or external reference. The  $^{1}\text{H}_{2}\text{O}$  signal has commonly been used as an internal reference for  $^{1}\text{H}$  MRS data (e.g. in LCModel). Unlike  $^{1}\text{H}$  MRS,  $^{31}\text{P}$  MRS does not have a reliable internal reference; therefore external references have been generally used [1]. However, it is difficult to validate the result of an external reference. In this work, we propose to use phosphocreatine (PCr) concentration, obtained from *in vivo*  $^{1}\text{H}$  MRS in LCModel, as an internal reference for  $^{31}\text{P}$  metabolites quantification and compare it with the results determined by using the external reference of inorganic phosphate (Pi). Our goal is to validate quantification of  $^{31}\text{P}$  metabolites using Pi phantom data, thus eliminating the need for *in vivo*  $^{1}\text{H}$  scans while still affording the same capabilities of  $^{31}\text{P}$  metabolite quantification.

### **Methods:**

All MR studies were performed on a Varian 4T whole-body MR system using a <sup>31</sup>P-<sup>1</sup>H dual head coil. Five healthy volunteers were consented and participated in the study. The region of interest for this study was an 8 ml and 12 ml voxel from the anterior cingulate (ACG) for <sup>1</sup>H and <sup>31</sup>P MRS, respectively. The <sup>1</sup>H spectra were obtained using the single-voxel PRESS sequence (2 x 2 x 2 cm voxel size) and the <sup>31</sup>P spectra were acquired using a one-pulse 3D MRSI sequence with a three-dimensional spherical sampling scheme (13 x 13 x 13 data matrix, 24 x 24 x 24 cm FOV). A 3D MDEFT image was also acquired for the determination of tissue contents within MRS voxels and the voxel positioning. Analysis of the <sup>31</sup>P data was performed by the single voxel reconstruction method, which allows spatial positioning of the center of the <sup>31</sup>P spectral voxels to be the same as that of the <sup>1</sup>H MRS voxels. *In vitro* <sup>31</sup>P phantom data were ascertained from a 50mM Pi solution using the same sequence and coil as the *in vivo* <sup>31</sup>P MRSI studies. For comparison, two methods were used for data analysis: the first method relies on PCr levels of *in vivo* <sup>31</sup>P data while the second method uses Pi levels of *in vitro* <sup>31</sup>P phantom data for the reference to determine the *in vivo* <sup>31</sup>P metabolites concentration.

For method 1, <sup>1</sup>H MRS data were analyzed by LCModel with water-suppressed and water-unsuppressed <sup>1</sup>H MRS data. The concentration of PCr can be determined by using the <sup>1</sup>H<sub>2</sub>O signal as a reference from the water-unsuppressed MRS at the same voxel. Then, one can use the determined PCr concentration as an internal reference to estimate all other <sup>31</sup>P metabolite concentrations with <sup>31</sup>P MRS spectra. All *in vivo* data (<sup>1</sup>H and <sup>31</sup>P) were quantified and accounted for tissue volume (compartmentalization), receiver gain, and relaxations. Here, we assume that the "partial volume" effect of these two voxels (8 *vs.* 12 ml) is negligible.

Method 2 used a two-liter spherical phantom containing a 50 mM Pi solution as an external reference to determine the *in vivo* <sup>31</sup>P metabolite concentrations. The phantom <sup>31</sup>P MRS data were collected temporally adjacent to the subject acquisition. The *in vivo* <sup>31</sup>P MRS data were also adjusted for tissue volume, receiver gain, and T1 relaxation when using *in vitro* Pi signal as a reference. All <sup>31</sup>P MRS data were analyzed by using JMRUI software.

### **Results:**

Figure 1 is a plot of Pearson correlation for all phosphorus metabolite concentrations (PCr,  $P_i$ ,  $\alpha$ -,  $\beta$ -, and  $\gamma$ -ATP, PME, and PDE) as determined by methods 1 and 2. A fitted line reveals a slope of 0.937 with an  $R^2$  value of 0.925, indicating an approximate 1:1 relationship between these two methods. In addition, all metabolite concentrations are well within reasonable and expected physiological values.

# **Discussion:**

Healthy subjects receiving both <sup>1</sup>H and <sup>31</sup>P MRSI scans has proven valuable in obtaining important bioenergetic information (e.g., ADP level) and the absolute concentration of high-energy phosphate metabolites [1], but the lengthy protocol may not be practical for patients with mental disorders or other physical conditions. The replacement of in vivo <sup>1</sup>H scans with in vitro <sup>31</sup>P scans will drastically reduce the amount of time that subjects spend inside the scanner, which is of particular benefit to clinically oriented studies. The slope of nearly one and high R<sup>2</sup> value indicate that phantom calibrated metabolite quantification is a very promising method. It should be noted that both methods are slightly limited in that <sup>31</sup>P T<sub>1</sub> and T<sub>2</sub> corrections cannot be made specific to gray and white matter content due to no such T<sub>1</sub> and T<sub>2</sub> data available, however both methods yield concentrations well within physiological ranges. Our results demonstrate that using the in vitro Pi signal as a <sup>31</sup>P external reference can be reliable and practical for the quantification of in vivo high-energy phosphate metabolites concentration.

References: 1) Pan JW and Takahashi K. Ann Neuro 2005;57:92-97




Fig 1. Comparisons of <sup>31</sup>P concentrations between two methods.